CRIS Current Research Information System

AUTERI, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.609
NA - Nord America 1.575
EU - Europa 1.169
AF - Africa 122
SA - Sud America 93
OC - Oceania 3
Totale 4.571
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.542
SG - Singapore 560
CN - Cina 495
IT - Italia 309
DE - Germania 181
VN - Vietnam 175
SE - Svezia 165
GB - Regno Unito 145
HK - Hong Kong 126
IN - India 109
BR - Brasile 66
KR - Corea 65
IE - Irlanda 59
RU - Federazione Russa 59
CI - Costa d'Avorio 54
FR - Francia 52
FI - Finlandia 50
NL - Olanda 48
TG - Togo 35
CA - Canada 23
ID - Indonesia 16
JO - Giordania 16
JP - Giappone 16
BE - Belgio 15
BG - Bulgaria 14
PL - Polonia 12
ZA - Sudafrica 12
CH - Svizzera 11
NG - Nigeria 10
AT - Austria 9
EE - Estonia 9
MX - Messico 9
TR - Turchia 8
UA - Ucraina 8
AR - Argentina 7
CZ - Repubblica Ceca 6
EC - Ecuador 6
PY - Paraguay 5
SC - Seychelles 5
TW - Taiwan 5
BD - Bangladesh 4
CO - Colombia 4
IR - Iran 4
LT - Lituania 4
AZ - Azerbaigian 3
LV - Lettonia 3
AL - Albania 2
AU - Australia 2
CL - Cile 2
EG - Egitto 2
ES - Italia 2
PK - Pakistan 2
RO - Romania 2
TN - Tunisia 2
BB - Barbados 1
CY - Cipro 1
DK - Danimarca 1
GE - Georgia 1
GF - Guiana Francese 1
HR - Croazia 1
HU - Ungheria 1
KE - Kenya 1
KH - Cambogia 1
MA - Marocco 1
MK - Macedonia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PH - Filippine 1
UY - Uruguay 1
Totale 4.571
Salva come PNG Salva come JPEG
Città #
Singapore 402
Ashburn 261
Chandler 197
Hefei 130
Hong Kong 124
Southend 110
Dong Ket 93
Santa Clara 77
Fairfield 69
Dallas 64
Beijing 63
Seoul 63
Bologna 59
Dublin 59
Abidjan 54
Princeton 52
Los Angeles 46
Milan 43
Boardman 42
Lomé 35
Helsinki 34
Houston 34
Hyderabad 34
Munich 34
Cornaredo 32
Seattle 32
Wilmington 30
Woodbridge 29
Ho Chi Minh City 27
New York 27
Hanoi 26
Redmond 26
Cambridge 23
Ann Arbor 22
Turin 21
Bremen 19
Buffalo 19
Nanjing 18
Amman 16
Brussels 15
Berlin 14
Sofia 14
Tokyo 14
Westminster 14
Bengaluru 13
Jakarta 13
Nuremberg 12
Lappeenranta 11
Shanghai 11
Frankfurt am Main 10
Rome 10
Toronto 10
Boydton 9
London 9
Monheim 9
Phoenix 9
Redondo Beach 9
Warsaw 9
Bern 8
Abeokuta 7
Chicago 7
Des Moines 7
Montreal 7
Perugia 7
Shijiazhuang 7
São Paulo 7
Changsha 6
Falkenstein 6
Guangzhou 6
Medford 6
Modena 6
Saint Petersburg 6
San Francisco 6
Stockholm 6
Brno 5
Casalecchio di Reno 5
Fremont 5
Norwalk 5
Qingdao 5
Shenyang 5
Tongling 5
Turku 5
Vienna 5
Zhengzhou 5
Amsterdam 4
Brooklyn 4
Changchun 4
Chennai 4
Falls Church 4
Florence 4
Leawood 4
Migliarino 4
Mountain View 4
Olalla 4
Paris 4
Pune 4
Redwood City 4
San Diego 4
Wenzhou 4
Abano Terme 3
Totale 2.979
Salva come PNG Salva come JPEG
Nome #
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 187
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 187
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 186
Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease 176
CIRCULATING CD34+ STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS 173
Mobilized Peripheral Blood versus Cord Blood: Insight into the distinct role of proinflammatory cytokines on survival, clonogenic ability, and migration of CD34+ cells 171
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera 171
STUDIO DELLA FUNZIONE E DEL PROFILO DEI MICRORNA IN MICROPARTICELLE CIRCOLANTI ISOLATE DA PAZIENTI ‘TRIPLI NEGATIVI’ E JAK2V617F MUTATI CON MIELOFIBROSI 169
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response 167
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis 162
A specific host/microbial signature of plasma-derived extracellular vesicles is associated to thrombosis and marrow fibrosis in polycythemia vera 160
TOWARD THE IDENTIFICATION OF A MICRORNA-BASED SIGNATURE OF CIRCULATING MICROPARTICLES FROM TRIPLE NEGATIVE AND JAK2(V617F) MUTATED PATIENTS WITH MYELOFIBROSIS 147
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 129
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis 125
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 123
Sustained response off therapy after fostamatinib: A chronic refractory ITP case report 123
Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients 122
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 119
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 111
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis 111
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. 105
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 105
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study 102
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 102
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis 100
Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies 99
The diagnostic role of next generation sequencing in uncovering isolated splenomegaly: A case report 92
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib 89
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study 87
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia 83
IDENTIFICATION OF POLYCYTHEMIA VERA-SPECIFIC BIOMARKERS OF OUTCOME BY NOVEL MULTIDIMENSIONAL ANALYSIS APPROACHES 73
Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients’ satisfaction 72
Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study 71
null 68
Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity 68
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 66
Liver and spleen shear-wave elastography in the diagnosis and severity staging of myeloproliferative diseases and myelofibrosis 64
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome 63
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy 63
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 62
Spleen and Liver Fibrosis Is Associated to Treatment Response and Prognosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms 59
Totale 4.712
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.931
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.931
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021232 0 0 0 0 0 17 7 23 50 3 8 124
2021/2022546 8 17 24 51 32 22 11 49 19 53 155 105
2022/2023760 56 100 45 104 62 78 15 46 137 28 57 32
2023/2024316 16 49 23 32 20 45 2 30 13 30 31 25
2024/20251.169 90 95 89 92 118 65 79 83 51 92 85 230
2025/20261.320 247 248 245 212 252 116 0 0 0 0 0 0
Totale 4.712